Adcendo raises EUR 51 Million in Series A Financing led by Novo Holdings and Ysios Capital to Advance Novel Antibody-Drug Conjugates for Treatment of Cancers

by Ysios Capital

Adcendo, a biotech company developing antibody-drug conjugates (ADCs) for the treatment of cancers, today announced the successful closing of a EUR 51 million (US$ 62 million) Series A financing. The ...

Read more
Subscribe to Directory
Write an Article

Highlight

Axon moves into Cloud Technology

by Axon Partners Group

cloud technology axon

Baker Tilly advises Business Software Gr...

by Baker Tilly

In February 2024, Business Software Group (BSG) launched a initial pub...

Photos Stream